Autres langues Verastem, Inc.

Actions

VSTM

US92337C2035

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 30/09/2026			Varia. 5j.	Varia. 1 janv.
8,050 ^USD	+1,64%		-1,59%	+4,27%

28/09	Verastem Oncology annonce la publication des résultats à long terme à deux ans de l’étude de phase 2 RAMP 201 évaluant AVMAPKI FAKZYNJA CO-PACK dans le cancer ovarien séreux de bas grade récidivant	CI
18/09	Le cours de Verastem ne valorise pas pleinement son potentiel de croissance, selon RBC	MT

Autres langues

28/09	Verastem Oncology Announces Publication in Gynecologic Oncology of Two-Year Median Follow-Up Data from RAMP 201 Study of AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer
28/09	Verastem Oncology Announces Publication Of Two-Year Long-Term Results From Phase 2 RAMP 201 Study Evaluating AVMAPKI FAKZYNJA CO-PACK In Recurrent Low-Grade Serous Ovarian Cancer
24/09	Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting
18/09	Verastem's Shares Not Fully Valuing its Growth Potential, RBC Says
14/09	RTW Biotech NAV rises 15% as public investments drive returns
08/09	Verastem Oncology Unveils New Clinical Data Highlighting The Best-In-Class Potential Of VS-7375, An Oral KRAS G12D (ON/OFF) Inhibitor Across Pancreatic, Lung, And Colorectal Cancers
08/09	Verastem Oncology to Unveil New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, Across Pancreatic, Lung, and Colorectal Cancers
02/09	Verastem Oncology to Participate in Upcoming September Investor Conferences
07/08	Verastem, Inc. Amends Note Purchase Agreement to Establish New Series of Senior Secured Revenue Notes Up to $75 Million
07/08	Verastem : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)
06/08	Verastem: Q2 Earnings Snapshot
06/08	Verastem, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
06/08	Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates
28/07	Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer
28/07	Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer
23/07	Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026
22/07	Verastem Oncology Doses First Patient in Target-D 202 Phase 2 Registration-Directed Trial of Vs-7375 for Kras G12d-Mutated Advanced Non-Small Cell Lung Cancer
22/07	Verastem Oncology Doses First Patient in TARGET-D 202 Phase 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer
02/07	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
29/06	Verastem, Inc.(NasdaqCM:VSTM) dropped from Russell Small Cap Comp Value Benchmark
29/06	Verastem, Inc.(NasdaqCM:VSTM) dropped from Russell 3000 Value Benchmark
29/06	Verastem, Inc.(NasdaqCM:VSTM) dropped from Russell 3000E Value Benchmark
29/06	Verastem, Inc.(NasdaqCM:VSTM) dropped from Russell Microcap Value Benchmark Index
29/06	Verastem, Inc.(NasdaqCM:VSTM) dropped from Russell 2500 Value Benchmark
29/06	Verastem, Inc.(NasdaqCM:VSTM) dropped from Russell 2000 Value Benchmark